Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093032 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1104704 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31482164 | 0.98 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL10129028 | 0.93 | SSTR4 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL14092960 | 0.93 | SSTR4 (0.36) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL25595886 | 0.91 | SSTR4 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL27361436 | 0.91 | SSTR4 (0.38) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL23260533 | 0.86 | SSTR4 (0.35) | SSTR4 | |
| SCHEMBL22433108 | 0.84 | SMN1; SMN2 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1104693 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013177284-A1 | HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177269-A2 | ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| WO-2013177292-A1 | TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2013-11-28 | — | — | WO | claimed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239794-A1 | PKC-Theta Modulators | EXSCIENTIA AI LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239794-A1 | PKC-Theta Modulators | EXSCIENTIA AI LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SLC6A1 3794/4885SLC6A11 4270/4885TSHR 3456/4885 |
| US-20240239794-A1 | PKC-Theta Modulators | PRKCQ, PRKCH, PRKCZ | SLC6A1 2602/4885SLC6A11 2563/4885TSHR 1952/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | SLC6A1 4810/4885SLC6A11 4322/4885TSHR 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.